|
|
The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will aim to assemble medical, surgical & radiation oncologists, and other key professionals at the same place. It will explore emerging facts that inspire the optimal management of early-stage breast cancer. The conference will provide an opportunity for healthy discussion on available adjuvant and neoadjuvant treatment options and controversies of developing clinical trial conclusions.
The conference will focus on the following topics:
- Are ER and HER2 accurate as subtype predictors?
- Is adjuvant therapy with 5-FU analogues a new standard of care?
- Is endocrine therapy of benefit in HER2-driven BC?
- Triple-negative locally-advanced breast cancer and no pCR—is there a role for PARP inhibitors?
- Clinical utility of preoperative therapy with HER2-targeted agents
- Pharmacogenomics and endocrine therapy selection
- Ongoing trials incorporating novel cytotoxic and biologic agents
Visitor Profile
Targeted visitors at Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy will be professionals interested in the treatment of breast cancer such as:
- Medical, Surgical, and Radiation Oncologists
- Nurses
- Physician Assistants
- Pharmacists
Organizer
Physicians’ Education Resource
